STOCK TITAN

PRECIGEN (PGEN) director granted RSUs, stock options and shares as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PRECIGEN, INC. director James S. Turley reported equity compensation awards rather than open-market trades. On March 10, 2026, he received 35,612 restricted stock units and options for 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. He also received 17,806 shares of common stock issued in lieu of a cash annual retainer of $62,500. The restricted stock units vest in full on March 10, 2027. Following these awards, his direct common stock holdings increased to 613,578 shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Turley James S

(Last) (First) (Middle)
20374 SENECA MEADOWS PARKWAY

(Street)
GERMANTOWN MD 20876

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/10/2026 A 17,806 A $3.51(1) 613,578 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 03/10/2026 A 35,612 (3) (3) Common Stock 35,612 $0 35,612 D
Option to Purchase Common Stock (Right to Buy) $3.51 03/10/2026 A 41,073 03/10/2026 03/10/2036 Common Stock 41,073 $0 41,073 D
Explanation of Responses:
1. The shares were issued to the reporting person in lieu of an annual retainer of $62,500.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
3. The RSUs vest in full on March 10, 2027.
/s/ James S. Turley, by Donald P. Lehr, as attorney-in-fact 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PRECIGEN (PGEN) director James S. Turley report?

Director James S. Turley reported equity compensation awards, not open-market trades. He received restricted stock units, stock options, and shares of common stock granted in lieu of a cash retainer, all dated March 10, 2026, increasing his direct holdings.

How many restricted stock units did the PRECIGEN (PGEN) director receive?

James S. Turley received 35,612 restricted stock units. Each RSU represents a contingent right to receive one share of PRECIGEN common stock. These units function as deferred equity compensation that will settle in company shares upon vesting.

When do James S. Turley’s PRECIGEN (PGEN) restricted stock units vest?

The restricted stock units granted to James S. Turley vest in full on March 10, 2027. Vesting means the units convert into the right to receive PRECIGEN common shares, subject to the grant terms and his continued service.

What stock options were granted to the PRECIGEN (PGEN) director?

James S. Turley was granted options covering 41,073 shares of PRECIGEN common stock at an exercise price of $3.51 per share. These options are exercisable through March 10, 2036, providing long-term equity-based compensation aligned with shareholder interests.

Why did PRECIGEN (PGEN) issue 17,806 common shares to its director?

PRECIGEN issued 17,806 common shares to James S. Turley in lieu of an annual cash retainer of $62,500. This shifts a portion of his board compensation from cash to equity, further tying his compensation to the company’s share performance.

What are James S. Turley’s PRECIGEN (PGEN) holdings after these transactions?

After the March 10, 2026 awards, James S. Turley directly holds 613,578 PRECIGEN common shares. This figure reflects his updated equity position following the grant of common stock, restricted stock units, and stock options disclosed in the Form 4.
Precigen Inc

NASDAQ:PGEN

View PGEN Stock Overview

PGEN Rankings

PGEN Latest News

PGEN Latest SEC Filings

PGEN Stock Data

1.16B
305.62M
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN